Literature DB >> 19884336

Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Ryan T Ranallo1, Robert W Kaminski, Tonia George, Alexis A Kordis, Qing Chen, Kathleen Szabo, Malabi M Venkatesan.   

Abstract

The ability of genetically detoxified lipopolysaccharide (LPS) to stimulate adaptive immune responses is an ongoing area of investigation with significant consequences for the development of safe and effective bacterial vaccines and adjuvants. One approach to genetic detoxification is the deletion of genes whose products modify LPS. The msbB1 and msbB2 genes, which encode late acyltransferases, were deleted in the Shigella flexneri 2a human challenge strain 2457T to evaluate the virulence, inflammatory potential, and acquired immunity induced by strains producing underacylated lipid A. Consistent with a reduced endotoxic potential, S. flexneri 2a msbB mutants were attenuated in an acute mouse pulmonary challenge model. Attenuation correlated with decreases in the production of proinflammatory cytokines and in chemokine release without significant changes in lung histopathology. The levels of specific proinflammatory cytokines (interleukin-1beta [IL-1beta], macrophage inflammatory protein 1alpha [MIP-1alpha], and tumor necrosis factor alpha [TNF-alpha]) were also significantly reduced after infection of mouse macrophages with either single or double msbB mutants. Surprisingly, the msbB double mutant displayed defects in the ability to invade, replicate, and spread within epithelial cells. Complementation restored these phenotypes, but the exact nature of the defects was not determined. Acquired immunity and protective efficacy were also assayed in the mouse lung model, using a vaccination-challenge study. Both humoral and cellular responses were generally robust in msbB-immunized mice and afforded significant protection from lethal challenge. These data suggest that the loss of either msbB gene reduces the endotoxicity of Shigella LPS but does not coincide with a reduction in protective immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884336      PMCID: PMC2798193          DOI: 10.1128/IAI.00533-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

Review 1.  Live-attenuated Shigella vaccines.

Authors:  Malabi M Venkatesan; Ryan T Ranallo
Journal:  Expert Rev Vaccines       Date:  2006-10       Impact factor: 5.217

2.  Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Authors:  Ryan T Ranallo; Sejal Thakkar; Qing Chen; Malabi M Venkatesan
Journal:  Vaccine       Date:  2006-12-20       Impact factor: 3.641

3.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Developing live Shigella vaccines using lambda Red recombineering.

Authors:  Ryan T Ranallo; Shoshana Barnoy; Sejal Thakkar; Tonia Urick; Malabi M Venkatesan
Journal:  FEMS Immunol Med Microbiol       Date:  2006-08

5.  Expression of toll-like receptor 2 and 4 in lipopolysaccharide-induced lung injury in mouse.

Authors:  Takuma Saito; Takashi Yamamoto; Toshihiro Kazawa; Humitake Gejyo; Makoto Naito
Journal:  Cell Tissue Res       Date:  2005-05-18       Impact factor: 5.249

6.  High vaccine efficacy against shigellosis of recombinant noninvasive Shigella mutant that expresses Yersinia invasin.

Authors:  Toshihiko Suzuki; Yuko Yoshikawa; Hiroshi Ashida; Hiroki Iwai; Takahito Toyotome; Hidenori Matsui; Chihiro Sasakawa
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

7.  Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a.

Authors:  S S Way; A C Borczuk; M B Goldberg
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

8.  Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Authors:  T S Coster; C W Hoge; L L VanDeVerg; A B Hartman; E V Oaks; M M Venkatesan; D Cohen; G Robin; A Fontaine-Thompson; P J Sansonetti; T L Hale
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

9.  The complete DNA sequence and analysis of the large virulence plasmid of Escherichia coli O157:H7.

Authors:  V Burland; Y Shao; N T Perna; G Plunkett; H J Sofia; F R Blattner
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

10.  A lethal role for lipid A in Salmonella infections.

Authors:  S A Khan; P Everest; S Servos; N Foxwell; U Zähringer; H Brade; E T Rietschel; G Dougan; I G Charles; D J Maskell
Journal:  Mol Microbiol       Date:  1998-07       Impact factor: 3.501

View more
  17 in total

1.  Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant.

Authors:  Qingke Kong; David A Six; Qing Liu; Lillian Gu; Kenneth L Roland; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

Review 2.  Shigella: a model of virulence regulation in vivo.

Authors:  Benoit Marteyn; Anastasia Gazi; Philippe Sansonetti
Journal:  Gut Microbes       Date:  2012-03-01

3.  Transcriptional analysis of the MrpJ network: modulation of diverse virulence-associated genes and direct regulation of mrp fimbrial and flhDC flagellar operons in Proteus mirabilis.

Authors:  Nadine J Bode; Irina Debnath; Lisa Kuan; Anjelique Schulfer; Maureen Ty; Melanie M Pearson
Journal:  Infect Immun       Date:  2015-04-06       Impact factor: 3.441

Review 4.  Lipid A structural modifications in extreme conditions and identification of unique modifying enzymes to define the Toll-like receptor 4 structure-activity relationship.

Authors:  Alison J Scott; Benjamin L Oyler; David R Goodlett; Robert K Ernst
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-01-17       Impact factor: 4.698

Review 5.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

6.  Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism.

Authors:  Dustin Dovala; Christopher M Rath; Qijun Hu; William S Sawyer; Steven Shia; Robert A Elling; Mark S Knapp; Louis E Metzger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

7.  Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.

Authors:  Jian Sha; Michelle L Kirtley; Christina J van Lier; Shaofei Wang; Tatiana E Erova; Elena V Kozlova; Anthony Cao; Yingzi Cong; Eric C Fitts; Jason A Rosenzweig; Ashok K Chopra
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

8.  Polymyxin B resistance in El Tor Vibrio cholerae requires lipid acylation catalyzed by MsbB.

Authors:  Jyl S Matson; Hyun Ju Yoo; Kristina Hakansson; Victor J Dirita
Journal:  J Bacteriol       Date:  2010-02-12       Impact factor: 3.490

9.  Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Authors:  S Barnoy; K I Jeong; R F Helm; A E Suvarnapunya; R T Ranallo; S Tzipori; M M Venkatesan
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

10.  Intracellular Shigella remodels its LPS to dampen the innate immune recognition and evade inflammasome activation.

Authors:  Ida Paciello; Alba Silipo; Luigi Lembo-Fazio; Laura Curcurù; Anna Zumsteg; Gaëlle Noël; Valeria Ciancarella; Luisa Sturiale; Antonio Molinaro; Maria Lina Bernardini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.